TAG:
Diagnostic tests
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example, such a test may be used to confirm that a person is free from disease, or to fully diagnose a disease, including to sub-classify it regarding severity and susceptibility to treatment. Diagnostic tests help physicians make clinical decisions for patient care.
Some diagnostic tests are parts of a physical examination that require only simple tools in the hands of a skilled practitioner, and can be performed in an office environment. Some other tests require elaborate equipment used by medical technologists in clinical laboratories, or the use of a sterile operating theater environment.
Some tests require samples of tissue or body fluids to be sent off to a pathology lab for further analysis. Some simple chemical tests, such as urine pH, can be measured directly in the doctor’s office.
The validity of such test results produced in each laboratory is entirely dependent on the measures employed before, during, and after each assay. Consistency in the production of good results requires an overall program that includes quality assurance, quality control, and quality assessment.
Diagnostic tests can be classified into three categories: invasive, minimally invasive and non-invasive.
Every test that shows an association between test results and the target disease is potentially useful. If it is not on its own thought to be useful, then a combination of it with other test results and/or data can potentially lead to a post-test probability that is thought to be high enough to rule the diagnosis in or low enough to rule the diagnosis out.
Companion diagnostics have also been developed to preselect patients for specific treatments based on their own biology, where such targeted therapy may hold promise in personalized treatment of diseases such as cancer.
Growing acceptance of companion diagnostics is a trend with the potential to greatly increase the value that clinical pathology laboratory testing delivers to physicians, patients, and payers. It has become increasingly common for pharmaceutical companies to make agreements with in vitro diagnostics (IVD) manufacturers to develop a companion diagnostic test specifically for a therapeutic drug under development by that pharmaceutical company.
As most pathologists and clinical managers know, use of a companion diagnostic test is expected to add precision to the physician’s decision to prescribe therapeutic drugs.
December 31, 2007 “Intelligence: Late Breaking Lab News”
There’s late-breaking news affecting new federal rules for the anti-markup provisions scheduled to become effective on January 1, 2008. Just days ago, the federal Centers for Medicare & Medicaid Services…
Busy Year Demonstrated By Top Ten Lab Stories
CEO SUMMARY: As it turns out, 2007 has been an action-packed year with lots of events, plenty of changes, and the promise of even faster evolution across all sectors of the lab testing marketplace. THE D…
Medicare Rules Tighten Anatomic Path Mark-ups
CEO SUMMARY: Effective on January 1, 2008, new rules take effect that restrict the circumstances under which physicians can mark up the anatomic pathology services provided to their patients. However, ambiguities in how the rules are written are likely to make the intent of the new rules …
Are Feds Ready to Strike at TC/PC Arrangements?
CEO SUMMARY: Pathologists and laboratory directors will want to pay attention to the proposed rules published by the Centers for Medicare and Medicaid Services on July 2, 2007. The document is a grab bag of proposals and rules that would significantly curb many common ancillary services a…
Procter & Gamble Moves into the Neighborhood
LAST MONTH, A NEW RESIDENT BOUGHT INTO THE LABORATORY TESTING NEIGHBORHOOD. Procter & Gamble Company spent a third of a billion dollars to enter a joint venture with Inverness Medical Products, Inc., with the specific goal of selling diagnostic test kits to consu…
Inverness Buys Biosite, Has New Venture with P&G
CEO SUMMARY: On the same day that Inverness Medical Innovations announced that it would acquire Biosite, thus beating out Beckman Coulter in the bidding war for Biosite, Inverness also announced that it had entered into a joint venture with Procter & Gamble. Together, the two companie…
Joint Venture Launches Molecular Pathology Lab
CEO SUMMARY: As genomic medicine advances, researchers into various diseases quickly recognize the need to incorporate molecular pathologists onto their teams. In Grand Rapids, Michigan, a large integrated health system and a private research institute have come together to jointly fund a…
Ventana & Cytyc Fall Short, Danaher Wins the Prize
WHEN Danaher Corporation’s high bid for Vision Systems Limited of Melbourne, Australia, was accepted last month, it appeared to be simply another acquisition by a large U.S. manufacturer. But, in fact, there are four reasons this transaction is significant to patho…
Docs’ Pricing, Outcomes Available to the Public
CEO SUMMARY: Transparency of provider prices and outcomes is coming to healthcare. A new executive order directs all federal agencies to collect and publish data on prices and outcomes for healthcare providers serving beneficiaries of government health programs. At the same time, private …
Bio-Reference Enters DNA Sequencing Market
CEOSUMMARY: Bio-Reference Laboratories has just placed an unexpected bet on the wide-open opportunities in genetic testing. The acquisition of GeneDX brings it a respected team of geneticists, capabilities in full DNA sequencing, and a proven track record in testing for rare and complex h…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.